Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline
NCT02123576Terminated
- Start
- Apr 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of pentoxifylline in hepatorenal syndrome (HRS) (2 arms). Primary endpoint: Number of Participants With Treatment Success at 14 days. Started Apr 2014; status: terminated.
02
Drugs
pentoxifylline
03
Conditions
hepatorenal syndrome (HRS)
Beyond the preview
Go deeper on NCT02123576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02123576.